Sanofi's Aubagio Gets Australian Nod - Analyst Blog

By
A A A

Sanofi ( SNY ) and its subsidiary Genzyme recently announced that their oral candidate for relapsing forms of multiple sclerosis (RMS), Aubagio (teriflunomide) 14 mg, has received Australian Therapeutic Goods Administration (TGA) approval. The TGA approved Aubagio as a once-daily treatment for patients with RMS.

We note that Australia is the second country where Aubagio received approval. On September 12, 2012, the US Food and Drug Administration (FDA) approved Aubagio as a once-daily treatment for patients with RMS. Aubagio is currently under regulatory review in the EU with a final decision expected in the first quarter of 2013.

The Australian approval came on the basis of data from a pivotal phase III study (TEMSO) in patients with RMS. In the trial, Aubagio demonstrated promising efficacy and safety profile.

Competition in the oral multiple sclerosis (MS) market is intense. Novartis ' ( NVS ) Gilenya already has a lead in the oral MS market with the product being approved in September 2010. Another major competitor could be Biogen Idec's ( BIIB ) BG-12, which is currently under regulatory review in the US and EU.

We are pleased with Sanofi's progress with its pipeline. Over the last few months, several of Sanofi's pipeline candidates gained approval including US approval of Aubagio for RMS and US approval of Zaltrap (aflibercept) as a combination therapy for treatment-experienced patients suffering from metastatic colorectal cancer. Recently, the CHMP also recommended the approval of Zaltrap and diabetes candidate, Lyxumia (lixisenatide).

We expect Sanofi to continue to contain operating costs in order to increase earnings in the face of weakening sales of some of its biggest products. We also expect the company to pursue bolt-on acquisitions.



BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BIIB , MS , NVS , SNY , TGA

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

78%
71%
100%
100%
100%

Most Active by Volume

67,310,517
  • $100.53 ▲ 1.38%
50,893,843
  • $8.02 ▲ 2.56%
48,783,882
  • $10.25 ▲ 3.85%
43,859,280
  • $5.39 ▼ 4.09%
41,392,452
    $15.45 unch
31,440,620
  • $8.09 ▲ 3.45%
30,705,588
  • $3.11 ▲ 0.97%
28,829,509
  • $3.87 ▲ 19.44%
As of 8/19/2014, 04:03 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com